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OBJECTIVES: Poor adherence to ICS among individuals with asthma is common and 
associated with increased asthma symptoms and acute health care utilization; dimin-
ished quality of life; and increased health care costs. We sought to determine if a brief, 
automated telephone intervention using speech recognition (SR) technology improved 
ICS adherence among adults with asthma. METHODS: PEANUT is an ongoing clini-
cal trial involving 14,064 members of a health maintenance organization, aged 18 
years, taking medication for the management of asthma. Participants were randomized 
to usual care (UC) or the 18-month SR arm. SR participants taking ICS receive 
monthly reﬁll reminder calls, as needed, based on dispensing data derived from the 
electronic medical record. The calls were designed using qualitative methods and 
provide educational information, explore barriers to adherence, and offer transfer to 
an automated reﬁll line as appropriate. The primary outcome is the continuous 
measure of medication adherence (CMA), a measure of medication days dispensed 
relative to total observation days. Preliminary results through the ﬁrst 8 months are 
presented. RESULTS: Of over 10,000 calls attempted so far, we successfully reached 
the target participant 45% of the time and left a voice message on an additional 40% 
of calls. CMA scores were signiﬁcantly higher for SR than UC participants (0.48 vs. 
0.45, p  0.01), with the strongest effects (a ﬁve percentage point net differential) in 
those aged 60 yrs.  CONCLUSIONS: Early results suggest a small, signiﬁcant inter-
vention effect. Because small changes in adherence on a population basis can have 
important public health beneﬁts, this study supports the potential value of SR-based 
adherence interventions for asthma and other chronic diseases.
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OBJECTIVES: To evaluate the cost-effectiveness, from the Mexican Health Care 
System perspective, of Truvada versus Combivir and Kivexa in the treatment of anti-
retroviral naïve HIV-1 infected patients METHODS: A Markov model was developed 
to assess the incremental cost effectiveness of Truvada vs Combivir and Kivexa. Clini-
cal data was derived from published clinical trials (Study 903 and CNA30024) and 
other secondary sources to create a model of disease progression and treatment pat-
terns. Both health care and treatment costs were considered. Costs were reported in 
2008 US dollar. Costs and health outcomes were discounted at 5%. A second-order 
probabilistic Monte Carlo sensitivity analysis was conducted to assess the effects of 
parameter uncertainty on the study ﬁndings. RESULTS: The model projects an accu-
mulated discounted cost to the Mexican health care system per patient receiving the 
Truvada regimen of US$28,776 compared to US$24,605 for the Kivexa regimen and 
US$22,999 for the Combivir regimen. The accumulated discounted effect is 5.85 
QALYs per patient receiving Truvada compared to 4.89 QALYs for Kivexa and 4.81 
QALYs for Combivir. This results in an incremental cost for Truvada and Kivexa vs. 
Combivir of US$5,805 per QALY and US$19,436 per QALY respectively. Consider-
ing a willingness to pay (WTP) threshold of $US 10, 000 per QALY there is a 90% 
probability that treatment with Truvada is cost-effective relative to Combivir 
 CONCLUSIONS: Results from these analyses suggest that in the Mexican setting, use 
of Truvada in place of standard Combivir and Kivexa for treatment of HIV is likely 
to be cost effective. These conclusions are supported by conservative assumptions and 
sensitivity analyses.
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OBJECTIVES: To compare treatment persistence and incremental cost-persistence 
ratios across individual new antidepressants (SSRIs and atypical antidepressants) as 
well as the associated direct health care costs in the adult population covered by the 
public drug program of Quebec. METHODS: A retrospective cohort was conducted 
in a random sample of 13,936 adults age 18–64 years old covered by the Quebec 
public drug program and who initiated an antidepressant treatment in 2003. Persis-
tence was deﬁned as treatment duration of at least 6 months regardless of whether a 
product switch occurred. Economical impact was assessed over the ﬁrst year of treat-
ment through drug costs (antidepressants and all other drugs), medical services costs 
(psychiatric- or non-psychiatric), hospitalization costs, and total health care costs. 
Comparisons across products were conducted using the incremental cost-persistence 
ratio (ICPR). RESULTS: Treatment non-persistence ranged from 60.4% (paroxetine) 
to 65.1% (citalopram). The product associated with the highest total health care costs 
was citalopram (CDN$2653) and the lowest was venlafaxine (CND$2168). Fluvox-
amine had the lowest mean antidepressant costs (CND$215) and venlafaxine 
(CND$309) the highest; ﬂuoxetine was associated with the lowest medical services 
costs (CND$473) and hospitalization costs (CND$702), and citalopram with the 
highest for both types of costs: CND$559 for medical services and CND$970 for 
hospitalizations, respectively. Antidepressant costs, other drug costs, medical services 
costs and hospitalization costs accounted for, respectively, 10.5% (CDN$249, 95%CI: 
245–254), 33.7% (CDN$796, 95%CI: 753–839), 21.2% (CDN$501, 95%CI: 488–
514) and 34.5% (CDN$816, 95%CI: 769–862) of the total costs. The ICPR for total 
health care costs ranged from CDN$119 (ﬂuoxetine) to CDN$1,283 (paroxetine). 
CONCLUSIONS: Total costs were similar across products except for citalopram, 
which was more costly. In our ICPR analyses, paroxetine, ﬂuoxetine and venlafaxine 
appear to be the best choice compared to the other antidepressant alternatives.
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OBJECTIVES: Although serotonin reuptake inhibitors (SSRIs) are considered cost-
effective medications to treat major depressive disorders, they are associated with sig-
niﬁcant dosage adjustments at treatment initiation. This study examined whether 
dose-titration for SSRIs at initiation was associated with increased resource utilization 
and costs. METHODS: A nationally representative cohort of individuals in the United 
States with MDD was identiﬁed in a large managed care database between January 
1, 2004 and December 31, 2006. A study-speciﬁc titration-algorithm was used to 
identify patients who had dose-titration vs. not, within the ﬁrst eight weeks of SSRI 
therapy initiation. We calculated propensity scores and identiﬁed a 1:1 matched cohort 
of titrating vs. non-titrating patients. We used univariate and multivariate statistical 
tests to compare mean therapeutic days, health care service utilization and costs 
between the two groups during the ﬁrst 8 weeks and ﬁrst 6 months of treatment initia-
tion. RESULTS: At 8 weeks, The dose-titrated cohort was estimated to have a 30% 
decrease in adjusted mean number of therapeutic days (38 vs. 54, p  0.001), a 64% 
increase in depression-related outpatient visits (1.8 vs. 1.1, p  0.001), a 74% increase 
in depression-related outpatient expenditures ($136 vs. $78, p  0.001), a 105% 
increase in depression-related psychiatrist visits (0.72 vs. 0.35, p  0.001), an increase 
in anti-depressant pharmacy costs ($138 vs. $85, p  0.001), and an increase in other 
pharmacy costs ($214 vs. $144, p-value  0.001), compared to the matched non-titrat-
ing patient cohort. Signiﬁcant differences in the same outcomes at 6 months were also 
observed. CONCLUSIONS: MDD patients who are dose-titrated with SSRIs at initia-
tion consume more medical and pharmacy resources and have more days at a sub-
therapeutic dose. Thus, antidepressants that do not require dose-titration may be 
cost-beneﬁcial to payers of health care.
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OBJECTIVES: To estimate the cost effectiveness and long-term combined effects of 
Posaconazole versus ﬂuconazole/itraconazole (standard azole) therapy in the prophy-
laxis against invasive fungal Infections among high-risk neutropenic patients in 
Mexico METHODS: A previously validated Markov model was used to compare the 
projected lifetime costs and effects of two theoretical groups of patients, one receiving 
Posaconazol and the other receiving standard azole. The model estimates total costs, 
numbers of IFIs, and QALY per patient in each prophylaxis group. To extrapolate 
trial results to a lifetime horizon, the model was extended with one-month Markov 
cycles in which mortality risk is speciﬁc to the underlying disease. Data on the proba-
bilities of IFI were obtained from Study Protocol PO1899. Drug costs were taken from 
average wholesale drug reports for 2008. Cost and health effects were discounted at 
5% according to the Mexican guideline. The analysis was conducted from the Mexican 
health care perspective using 2008 unit cost prices RESULTS: Our model projects an 
accumulated cost to the Mexican health care system per patient receiving the Posacon-
azol regimen of US$5634 compared to US$7463 for the standard azole regimen. The 
accumulated discounted effect is 3.13 LY or 2.25 QALYs per patient receiving 
Posaconazol, compared to 2.96 LY or 2.13 QALYs per patient receiving standard 
azole. Posaconazol remained the dominant strategy across each scenario. Probabilistic 
sensitivity analysis tested numerous assumptions about the model cost and efﬁcacy 
parameters and found that the results were robust to most changes CONCLUSIONS: 
